Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.79 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.79 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.79 |
| ▸ | ITGAV | P06756 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928041 | 0.99 | ITGB1 (0.81) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2962384 | 0.98 | ITGB1 (0.80) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2947742 | 0.93 | ITGB1 (0.85) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2957040 | 0.93 | ITGB1 (0.78) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2951581 | 0.92 | ITGB1 (0.88) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2962382 | 0.92 | ITGB1 (0.80) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2927543 | 0.91 | ITGB1 (0.75) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2947564 | 0.91 | ITGB1 (0.86) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2959029 | 0.91 | ITGB1 (0.76) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2953329 | 0.89 | ITGB1 (0.97) | ITGB1ITGA4ITGB7ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | claimed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | claimed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | claimed |
| EP-1507775-B1 | HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA4 INTEGRINS | ELAN PHARM INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-7427628-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | claimed |
| US-20070027131-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | ELAN PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | claimed |
| US-7135477-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1507775-A4 | HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA4 INTEGRINS | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-7026328-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | claimed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | claimed |
| EP-1507775-A1 | HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA4 INTEGRINS | Elan Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | WYETH | 2004-07-15 | — | — | US | claimed |
| WO-2003099809-A1 | HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY α4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8410115-B2 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | WYETH | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | IL4, PSMA4, SCN4A | ITGB1 277/4885ITGA4 27/4885ITGB7 464/4885 |
| US-20070027131-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | VCAM1, ITGB4, ICAM1 | ITGB1 9/4885ITGA4 4/4885ITGB7 55/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | VCAM1, ICAM1, ITGB4 | ITGB1 15/4885ITGA4 4/4885ITGB7 49/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.